Log in
Enquire now
Ovid Therapeutics

Ovid Therapeutics

A biotechnology company specializing in creating therapeutics for neurological disorders. It was founded in 2014 and is located in New York City.

OverviewStructured DataIssuesContributors

Contents

ovidrx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
0
Therapeutics
Therapeutics
Biomedical engineering
Biomedical engineering
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Engineering
Engineering
Location
Cambridge, Massachusetts
Cambridge, Massachusetts
0
United States
United States
New York
New York
New York City
New York City
0
B2X
B2C
B2C
0
B2B
B2B
0
B2B2C
B2B2C
CEO
Jeremy Levin
Jeremy Levin
0
Founder
Matthew J. During
Matthew J. During
0
Pitchbook URL
pitchbook.com/profiles...110258-92
Legal Name
Ovid Therapeutics Inc.0
Number of Employees (Ranges)
11 – 50
Email Address
info@ovidrx.com0
Phone Number
+164666176610
Full Address
New York, NY 1460 Broadway New York, NY 10036
New York, NY 441 9th Avenue New York NY, 100010
Cambridge, MA 245 Main Street Cambridge MA, 021420
CIK Number
1,636,6510
Place of Incorporation
Delaware
Delaware
0
Investors
Redmile Group
Redmile Group
Cormorant Asset Management
Cormorant Asset Management
Jennison Associates
Jennison Associates
Sphera Funds Management
Sphera Funds Management
Fidelity Investments
Fidelity Investments
Sanofi Ventures
Sanofi Ventures
Tekla Capital Management
Tekla Capital Management
IRS Number
465,270,8950
Founded Date
2014
0
Total Funding Amount (USD)
105,961,228
Latest Funding Round Date
January 23, 2017
Competitors
NeuroNascent
NeuroNascent
Zynerba Pharmaceuticals
Zynerba Pharmaceuticals
Brainstorm
Brainstorm
SAGE Therapeutics
SAGE Therapeutics
Marinus Pharmaceuticals
Marinus Pharmaceuticals
Business Model
Commerce
Stock Symbol
OVID0
Exchange
Nasdaq
Nasdaq
Glassdoor ID
2336992
Board of Directors
Jeremy Levin
Jeremy Levin
0
‌
Bart Friedman
0
‌
Barbara Duncan
0
CFO
‌
Jeffrey Rona
0
Latest Funding Type
Series C
Series C
NAICS Code
325,4120
Patents Assigned (Count)
3
COO
‌
Jason Tardio
0
Country
United States
United States

Other attributes

Company Operating Status
Active
Contact Page URL
ovidrx.com/contact/
SIC Code
2,8340
Ticker Symbol
OVID0
Wikidata ID
Q104481367
About

Ovid Therapeutics is a New York-based company with a focus on developing medicines for patients living with rare neurological disorders. The company partners with patient advocacy groups and foundations in order to better understand the community for whom it is working.It also collaborates with other biotechnology and pharmaceutical companies to develop its therapeutics, such as Takeda and Lundbeck.

Product

The company has multiple therapeutics that are in the process of going through clinical trials. It focuses on specific neurological disorders and develops drugs to treat those disorders. One such disorder is Angelman syndrome. The company is conducting clinical trials for both adolescents and adults for therapeutics such as gaboxadol.

FAnother disorder for which the company is developing therapeutics is Fragile X syndrome. The clinical trials also used the therapeutic gaboxadol. The studies for CDKL5 deficiency disorder and chromosome 15q duplication syndrome used the therapeutic soticlestat to seek results.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Ovid Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.